Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Cara Therapeutics, Inc. (CARA)  
$0.81 0.05 (5.96%) as of 4:30 Thu 5/16


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 49,830,000
Market Cap: 40.12(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.5201 - $3.85
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Cara Therapeutics is an early commercial-stage biopharmaceutical company focusing on a new treatment paradigm to improve the lives of patients suffering from pruritus. Co.'s KORSUVA injection is an FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease, in adults undergoing hemodialysis. Co. is developing an Oral KORSUVA (difelikefalin) formulation for the treatment of pruritus in patients with atopic dermatitis, and non-dialysis-dependent chronic kidney disease. Phase 2 trials of Oral KORSUVA (difelikefalin) are ongoing in primary biliary cholangitis, and in notalgia paresthetica patients with moderate-to-severe pruritus.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 21,862 62,418 74,924 183,344
Total Sell Value $18,576 $40,171 $82,171 $922,884
Total People Sold 3 3 4 8
Total Sell Transactions 6 8 12 32
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 307
  Page 12 of 13  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Vogelbaum Martin Director   –       •      –    2016-03-16 4 B $4.78 $727,834 I/I 152,273 2,820,330 2.1     -
   Kairouz Habib 10% Owner   –       –       •   2016-03-16 4 B $4.78 $727,834 I/I 152,273 2,820,330 1.5     -
   Schoell Josef Chief Financial Officer   •       –      –    2016-03-16 4 OE $0.78 $14,740 D/D 18,000 46,000     -
   Chalmers Derek T President & CEO   •       •      –    2016-03-15 4 OE $2.48 $24,800 D/D 10,000 1,097,292     -
   Menzaghi Frederique Ph.d. VP-Research & Development   •       –      –    2016-02-03 4 AS $9.00 $9,000 D/D (1,000) 129,000     -
   Menzaghi Frederique Ph.d. VP-Research & Development   •       –      –    2016-02-01 4 AS $9.05 $45,250 D/D (5,000) 130,000     -
   Lewis Michael E Chief Scientific Advisor   •       –      –    2016-01-26 4 AS $10.93 $79,374 D/D (7,262) 314,988     -
   Chalmers Derek T President & CEO   •       •      –    2016-01-06 4 AS $17.22 $215,250 D/D (12,500) 1,087,292     -
   Slagel Dean Director   –       •      –    2016-01-05 4 AS $17.01 $531,120 I/I (31,224) 1,314,338     -
   Menzaghi Frederique Ph.d. VP-Research & Development   •       –      –    2016-01-04 4 AS $16.80 $100,800 D/D (6,000) 135,000     -
   Slagel Dean Director   –       •      –    2015-12-31 4 AS $17.00 $217,192 I/I (12,776) 1,345,562     -
   Menzaghi Frederique Ph.d. VP-Research & Development   •       –      –    2015-12-01 4 AS $16.21 $97,260 D/D (6,000) 141,000     -
   Menzaghi Frederique Ph.d. VP-Research & Development   •       –      –    2015-11-02 4 AS $14.26 $85,560 D/D (6,000) 147,000     -
   Menzaghi Frederique Ph.d. VP-Research & Development   •       –      –    2015-10-01 4 AS $13.79 $83,715 D/D (6,000) 153,000     -
   Menzaghi Frederique Ph.d. VP-Research & Development   •       –      –    2015-09-01 4 AS $18.63 $130,410 D/D (7,000) 159,000     -
   Schoell Josef Chief Financial Officer   •       –      –    2015-08-18 4 B $22.10 $66,300 D/D 3,000 28,000 2.74     -
   Stauffer Joseph William Chief Medical Officer   •       –      –    2015-08-04 4 B $18.60 $37,200 D/D 2,000 13,442 2.74     -
   Menzaghi Frederique Ph.d. VP-Research & Development   •       –      –    2015-08-03 4 AS $21.41 $149,870 D/D (7,000) 166,000     -
   Menzaghi Frederique Ph.d. VP-Research & Development   •       –      –    2015-07-01 4 AS $12.22 $85,540 D/D (7,000) 173,000     -
   Lewis Michael E Chief Scientific Advisor   •       –      –    2015-07-01 4 AS $11.66 $84,675 D/D (7,262) 322,250     -
   Lewis Michael E Chief Scientific Advisor   •       –      –    2015-06-01 4 AS $9.50 $68,989 D/D (7,262) 329,512     -
   Slagel Dean Director   –       •      –    2015-05-19 4 S $10.00 $322,660 I/I (32,266) 1,358,338     -
   Slagel Dean Director   –       •      –    2015-05-18 4 S $10.04 $832,768 I/I (82,945) 1,390,604     -
   Slagel Dean Director   –       •      –    2015-05-15 4 S $10.00 $736,000 I/I (73,600) 1,473,549     -
   Lewis Michael E Chief Scientific Advisor   •       –      –    2015-05-01 4 AS $10.64 $77,268 D/D (7,262) 336,774     -

  307 Records found
  Previous  10  11  12  13   
  Page 12 of 13
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed